TRBC1 specific Immunotherapy showing promise for T cell Lymphoma treatment

Autolus Therapeutics tested the toxicity and efficacy of AUTO4, a TRBC1 specific CAR cell therapeutic on 10 relapsed/refractory T cell lymphoma patients. This treatment appears to be safe with only minimal toxicity. The CAR T cells were shown to be residing in the majority of patient lymph nodes.Ancell anti-TRBC1/Biotin (clone Jovi-1) was used to sort […]

TRBC1 specific Immunotherapy showing promise for T cell Lymphoma treatment Read More »

SARS COV2 mRNA extended dose interval yielded improved B cell response but no difference in T cell response

Recipients who received 2nd Covid booster with a longer than recommended interval from 1st immunization had improved specific antibody response, but asimilar T cell response. This differential effect was nullified by a 3rdbooster. “Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters” JI Ahmed, CM Card, et al.

SARS COV2 mRNA extended dose interval yielded improved B cell response but no difference in T cell response Read More »

PD-1 interaction is necessary for proper B cell memory development

“Is one lymphocyte’s brake another lymphocyte’s gas?” Thomas T Xu, Shiv Pillai. (Feb 7, 2025) Sci Immunol 10(104): eadw3656 doi: 10.1126/sciimmunol.adw365 PMID: 39919195 PD-1 (CD279) binding to its ligand PD-L1 (CD274) is down regulatory for T cell immune response in the context of cancer. However, studies are showing that this interaction is required for development

PD-1 interaction is necessary for proper B cell memory development Read More »

Cyclophilan A is a ligand for RAGE

Cyclophilin A is a ligand for RAGE in thrombo-inflammation Peter Seizer, David Heinzmann, et al. (March 2024) Cardiovascular Research 120(4): 385–402, https://doi.org/10.1093/cvr/cvad189 Ancell anti-human CD147 mAb was used for detection and to block activation of cells by Cyclophilan A Related Ancell Products anti-human CD147( EMMPRIN) mAb

Cyclophilan A is a ligand for RAGE Read More »

Non Classical Monocytes inhibit Cancer metastasis in mouse models

“Non Classical” (CCR2+ CD16++ CD14+ MHC Class II+ CD209+) subset of mouse monocytes were expanded using NOD2 small-molecule activators. CCR2 enabled these cells to infiltrate tumors and inhibit metastasis in mouse models of colon, lung, breast and melanoma through CCL6 recruitment of NK cells. The monocyte CCR2/CCL2 axis merits further investigation for cancer intervention! “Inducible

Non Classical Monocytes inhibit Cancer metastasis in mouse models Read More »

LTbR emerging as an important TAM checkpoint

Levels of LTbR (Lymphotoxin beta Recpeptor) on TAM (Tumor Associated Macrophage) inversely correlate with anti-tumor response, indicating an immunosuppresive role. This Chinese research group demonstrate that disrupting this expression in mice by silencing or knockout causes tumor regression in a mouse lung carcinoma model. “LTBR acts as a novel immune checkpoint of tumor-associated macrophages for

LTbR emerging as an important TAM checkpoint Read More »

RAGE and CD147 are both receptors for cyclophilin A and are drivers of thrombo inflammation.

“Cyclophilin A is a ligand for RAGE in thrombo-inflammation” P Seizer, D Heinzmann, et al. Cardiovascular Research (2024) 120: 385-402. https://doi.org/10.1093/cvr/cvad189 PMID: 38175781 Ancell anti-CD147 antibody (clone UM-8D6) was used to block monocyte chemotaxis, induce NfkB translocation and to stimulate MyD88 antigen upregulation in monocytes. Ancell anti-CD147 mAb products

RAGE and CD147 are both receptors for cyclophilin A and are drivers of thrombo inflammation. Read More »

Induction of Suppressive NK-like cells

“Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization” DC Chung, PS Ohashi, et al. J Immunol(2024) 212(12): 1904-1912. https://doi.org/10.4049/jimmunol.2300834 PMID: 38668728 This Toronto based research group used a combination of TGF-b1 and IL-15 to induce a CD103+/CD49a+ phenotype in peripheral blood derived NK cells. Co incubation with this NK cell line inhibited CD4

Induction of Suppressive NK-like cells Read More »

Ancell anti-CD11b and CD18 mAbs used to block Trogocytotic killing

Ancell mAbs were used by this Cal State Research group to block trogocytic killing of Triconomas Vaginelas parasite by human PLB-95 Neutrophil-Like-cells in vitro. Blocking CD11c and CD18 receptors on NLC with antibodies resulted in significant reduction of killing, implicting CR3 mediated complement fixation as the primary mechanism. “Complement receptor 3 is required for maximum

Ancell anti-CD11b and CD18 mAbs used to block Trogocytotic killing Read More »